iclight,
What control patients are you talking about?; ). You seem to forget that the only true control patients did not cross over to treatment and they are the ones Dr. Linda Liau said did quite poorly. I’d be happy to compare those patient outcomes to those who received DCVax-L, either early or late. That would not fit your narrative, however, and more than likely prove glaringly that low absolute lymphocyte patients had little to no chance without L being given early. I’d love to see that data but then again that might be part of the reason the trial for SOC/placebo patients was stopped abruptly which again might be something Mr. Neil Woodford and other bad actors got wind of through Ondra’s Ms Wolfe and were held off from trading because of all the way to the point of needing to remove him as fiduciary. Again, something that does not line up with your narrative. Best wishes.
Market Data 
Markets 
